Literature DB >> 32404990

2-Epi-anthracimycin, a new cytotoxic agent from the marine-derived actinomycete Streptomyces sp. OPMA00631.

Takashi Fukuda1,2, Kenichiro Nagai3, Akihiko Kanamoto4, Hiroshi Tomoda5.   

Abstract

A new cytotoxic agent designated as 2-epi-anthracimycin (1) was isolated along with anthracimycin and anthracimycin B (2-demethylanthracimycin) from the culture broth of the marine-derived actinomycete Streptomyces sp. OPMA00631. The structure of 1 was elucidated based on spectroscopic analyses (1D and 2D NMR data and ROESY correlations). Compound 1 exhibited cytotoxicity against Jurkat cells with an IC50 value of 50.5 μM in 20 h. The effect of 1 on the cell cycle distribution of Jurkat cells was investigated. Compound 1 (7.80 μM) increased G1 phase cells from 51.1 to 62.0% and conversely, decreased G2 and M phase cells from 30.7 to 19.3 % in 20 h. At a higher concentration, 1 (250 μM) markedly increased subG1 phase cells (1.9% at 0 h to 16.5% at 20 h), while the proportion of G1 phase cells was maintained (62.3%). These results suggest that 1 exhibits cytotoxicity against Jurkat cells by arresting the cell cycle at the G1 phase.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32404990     DOI: 10.1038/s41429-020-0309-2

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  1 in total

1.  A Novel mTOR Inhibitor; Anthracimycin for the Treatment of Human Hepatocellular Carcinoma.

Authors:  Tomoyuki Hayashi; Taro Yamashita; Hikari Okada; Naoki Oishi; Hajime Sunagozaka; Kouki Nio; Takehiro Hayashi; Yasumasa Hara; Yoshiro Asahina; Mariko Yoshida; Tomomi Hashiba; Tsuyoshi Suda; Takayoshi Shirasaki; Yasuhiro Igarashi; Koji Miyanouchi; Tatsuya Yamashita; Masao Honda; Shuichi Kaneko
Journal:  Anticancer Res       Date:  2017-07       Impact factor: 2.480

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.